NEW YORK, Oct. 21, 2025 /PRNewswire/ — ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today announced the appointment of Francis S. Collins, MD, PhD, to its board of directors. Dr. Collins, a pioneering…
